Overview

Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects

Status:
Not yet recruiting
Trial end date:
2023-11-23
Target enrollment:
Participant gender:
Summary
To determine the safety and tolerability of MG-ZG122 in Chinese healthy adult subjects
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai Mabgeek Biotech.Co.Ltd
Treatments:
Antibodies
Antibodies, Monoclonal